Pliant Therapeutics (PLRX) Cash from Financing Activities (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Cash from Financing Activities of $74000.0 for Q1 2026, down 85.14% year-over-year from $498000.0 in Q1 2025, and up 100.23% quarter-over-quarter from -$32.3 million in Q4 2025.
Pliant Therapeutics (PLRX) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Cash from Financing Activities for 8 consecutive years, with $74000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 85.14% year-over-year to $74000.0; the TTM figure through Mar 2026 stood at -$32.1 million (down 1858.13% YoY), while the FY2025 annual figure was -$31.7 million, down 237.12% from the prior year.
- Cash from Financing Activities rose to $74000.0 in Q1 2026 per PLRX's latest filing, from -$32.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $273.3 million in Q1 2023 and bottomed at -$32.3 million in Q4 2025.
- Historically, Cash from Financing Activities has averaged $30.8 million across 5 years, with a median of $391000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 178744.44% — and 2025, when it tumbled 31734.31%.
- Pliant Therapeutics' Cash from Financing Activities stood at $284000.0 in 2022, then fell by 22.89% to $219000.0 in 2023, then tumbled by 53.42% to $102000.0 in 2024, then sank by 31734.31% to -$32.3 million in 2025, then surged by 100.23% to $74000.0 in 2026.
- Business Quant data shows PLRX's Cash from Financing Activities at $74000.0 in Q1 2026, -$32.3 million in Q4 2025, and $72000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Dec 31, 2025 | -32.27 Mn |
| Dec 31, 2025 | -32.27 Mn |
| Sep 30, 2025 | 72,000.00 |
| Sep 30, 2025 | 72,000.00 |
| Mar 31, 2025 | 498,000.00 |
| Mar 31, 2025 | 498,000.00 |
| Dec 31, 2024 | 102,000.00 |
| Dec 31, 2024 | 102,000.00 |
| Sep 30, 2024 | 543,000.00 |
| Sep 30, 2024 | 543,000.00 |
| Jun 30, 2024 | 684,000.00 |
| Jun 30, 2024 | 684,000.00 |
| Mar 31, 2024 | 21.79 Mn |
| Mar 31, 2024 | 21.79 Mn |
| Dec 31, 2023 | 219,000.00 |
| Dec 31, 2023 | 219,000.00 |
| Sep 30, 2023 | 699,000.00 |
| Sep 30, 2023 | 699,000.00 |